About Us

We address the underlying causes of ophthalmic diseases

Enhancing Lives & Better Vision

Okogen is an ophthalmic specialty pharmaceutical company focused on developing the leading treatment for both bacterial and viral conjunctivitis.

Our lead product candidate, OKG-0303, is being developed to treat infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial agent.

There are 6 million new cases of acute conjunctivitis per year in United States.

Meet the Team


Bradford A. Conlan

Executive Chairman and CEO
Read More

Joshua H. Moriarty

Chief Operating Officer and Board Member
Read More

Board of Directors

Brian M Strem, PhD

Read More

Eric Daniels, MD, MBA

Read More

Quinton Oswald

Read More

Scientific & Medical Advisory Board

Francis Mah, MD

Jay Pepose, MD, PhD

John Sheppard, MD

Russel Van Gelder, MD, PhD

Stephanie Watson, MD